NCT06438796View on ClinicalTrials.gov

Blinatumomab Maintenance After Allo-HSCT

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

59

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions

High Risk Acute Lymphoblastic Leukemia

Interventions

DRUG

Blinatumomab

Maintenance therapy with Blinatumomab initiation: 90 days to 120 days post-transplantation

All Listed Sponsors

lead

Ruijin Hospital

OTHER